Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Compass Pathways has a “Moderate Buy” consensus rating from 17 analysts: 14 Buys, one Strong Buy, one Hold and one Sell. The average 12-month price target is $23.36, well above the reported share price of $13.38.
• Recent analyst actions were generally positive: Evercore upgraded the stock to “Outperform” with a $21 target, while Canaccord Genuity raised its target to $20; HC Wainwright maintained a Buy rating but lowered its target from $70 to $65.
• The company remains highly speculative, reporting a quarterly EPS loss of $1.88 versus the $0.39 consensus estimate. Institutional investors and hedge funds own 46.19% of the shares, while CMPS trades near its 12-month high and has a beta of 2.50.

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has earned an average rating of "Moderate Buy" from the seventeen research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, fourteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $23.3571.

Several analysts have weighed in on CMPS shares. HC Wainwright dropped their price objective on Compass Pathways from $70.00 to $65.00 and set a "buy" rating for the company in a report on Friday. Canaccord Genuity Group lifted their price target on shares of Compass Pathways from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Friday, June 26th. Evercore raised shares of Compass Pathways from an "in-line" rating to an "outperform" rating and set a $21.00 price target for the company in a research note on Wednesday, July 8th. TD Cowen restated a "buy" rating on shares of Compass Pathways in a report on Monday, June 1st. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Compass Pathways in a research note on Tuesday, July 7th.

Key Compass Pathways News

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright retained its Buy rating and $65 target price for Compass Pathways. The target remains well above recent trading levels and reflects the analyst’s longer-term confidence in the company’s pipeline and commercial potential.
• Neutral Sentiment: The reported short-interest data shows zero shares short and a zero-day short-interest ratio, while also reporting an undefined percentage increase. Because the figures appear internally inconsistent, they provide no reliable signal about near-term buying pressure or bearish sentiment.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple periods, including Q3 2026 to $(0.43), FY2026 to $(1.58), FY2027 to $(1.56), FY2028 to $(0.23), FY2029 to $1.66, and FY2030 to $4.06. The largest revisions push back the expected earnings outlook: FY2028 changed from $1.64 to a loss, FY2029 fell from $3.78 to $1.66, and FY2030 declined from $6.59 to $4.06.

Institutional Investors Weigh In On Compass Pathways

Hedge funds have recently bought and sold shares of the company. Corient Private Wealth LLC increased its stake in Compass Pathways by 3.2% in the 4th quarter. Corient Private Wealth LLC now owns 38,438 shares of the company's stock worth $265,000 after purchasing an additional 1,200 shares during the period. EverSource Wealth Advisors LLC lifted its position in Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company's stock valued at $26,000 after purchasing an additional 1,920 shares during the last quarter. Conservest Capital Advisors Inc. boosted its stake in shares of Compass Pathways by 24.6% during the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company's stock valued at $175,000 after purchasing an additional 5,000 shares during the period. Persistent Asset Partners Ltd purchased a new stake in shares of Compass Pathways during the fourth quarter valued at approximately $38,000. Finally, Raymond James Financial Inc. grew its holdings in shares of Compass Pathways by 82.7% in the third quarter. Raymond James Financial Inc. now owns 13,763 shares of the company's stock worth $79,000 after purchasing an additional 6,228 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Compass Pathways Price Performance

Shares of CMPS stock opened at $13.38 on Wednesday. Compass Pathways has a 12 month low of $3.97 and a 12 month high of $15.40. The company has a market capitalization of $1.81 billion, a P/E ratio of -2.90 and a beta of 2.50. The stock has a 50 day moving average of $12.57 and a two-hundred day moving average of $9.44. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($1.49). As a group, equities analysts expect that Compass Pathways will post -1.26 EPS for the current year.

About Compass Pathways

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source